Mycobacterium Infections accounted for a 1.9% share of the global clinical trials within the Infectious Disease therapy area in 2021, registering a decrease of 1.9% when compared with the last ten-year average of 3.8% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Non-industry sponsored trials outnumber industry sponsored trials for Mycobacterium Infections
Industry sponsored trials held a 29.8% share of all the clinical trials for Mycobacterium Infections indication in 2021, registering a decrease of 2.6% when compared with the ten-year average of 32.4%. Non-industry sponsored trials accounted for a 70.2% share in 2021, registering an increase of 2.6% over the ten-year average of 67.6%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored Mycobacterium Infections trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored Mycobacterium Infections trials, accounting for a 56.7% share in 2021, when compared with the five-year average of 65.1% and ten-year average of 52.1%.
Europe was at the second position with a 30.0% share in 2021, over the five-year average of 30.9% and ten-year average of 38.8%, followed by Middle East and Africa with a 10.0% share in 2021, as against five-year and ten-year averages of 18.7% and 20.9% respectively.
North America stood fourth with a 3.3% share in 2021, compared with the five-year average of 7.2% and ten-year average of 9.2%, followed by South and Central America with a 0.0% share in 2021, over five-year and ten-year averages of 8.4% and 7.6% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
China was the top country for industry sponsored Mycobacterium Infections trials, accounting for a 30.0% share in 2021, as against the five-year average of 38.7% and ten-year average of 24.5%.
Russia held a 30.0% share in 2021, over the five-year average of 16.3% and ten-year average of 24.7%, followed by Japan with a 10.0% share in 2021, compared with the five-year and ten-year averages of 4.4% and 3.4% respectively.
South Korea held a 6.7% share in 2021, as against the five-year average of 9.3% and ten-year average of 6.5%.
Iran held a 6.7% share in 2021, over the five-year and ten-year averages of 0.0% and 0.0% respectively.
Top regions of non-industry sponsored Mycobacterium Infections trials
Asia-Pacific was the top region for non-industry sponsored Mycobacterium Infections trials, accounting for a 44.9% share in 2021 when compared with the five-year average of 57.8% and ten-year average of 49.4%.
Middle East and Africa was at the second position with a 39.1% share in 2021, over the five-year and ten-year averages of 26.6% and 31.5% respectively, followed by Europe with a 15.9% share in 2021, as against the five-year average of 16.0% and ten-year average of 18.1%.
North America stood at the fourth position with a 13.0% share in 2021, compared with the five-year average of 11.6% and ten-year average of 10.4%, followed by South and Central America with a 5.8% share in 2021, over the five-year and ten-year averages of 6.9% and 6.1% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
South Africa was the top country for non-industry sponsored Mycobacterium Infections trials, accounting for a 21.7% share in 2021, as against the five-year average of 16.1% and ten-year average of 18.5%.
China held a 17.4% share in 2021, over the five-year average of 24.5% and ten-year average of 18.4%, followed by India with a 15.9% share, compared with the five-year and ten-year averages of 12.5% and 10.5% respectively.
The US held a 13.0% share in 2021, as against the five-year average of 8.7% and ten-year average of 8.2%.
Uganda held a 7.2% share in 2021, over the five-year average of 7.0% and ten-year average of 6.3%.
Phase I trials lead industry sponsored clinical trials for Mycobacterium Infections in 2021
Phase I trials held a 64.5% share of industry sponsored clinical trials for Mycobacterium Infections in 2021, over the five-year average of 63.6% and ten-year average of 55.1%.
Phase II trials held a 22.6% share in 2021, as against the five-year average of 15.1% and ten-year average of 18.1%. Phase III trials held a 9.7% share in 2021, compared with the five-year and ten-year averages of 14.7% and 16.7% respectively.
Phase IV trials held a 3.2% share in 2021, over the five-year average of 6.6% and ten-year average of 10.1%.
Phase II trials lead non-industry sponsored clinical trials for Mycobacterium Infections in 2021
Phase II trials held a 34.2% share of non-industry sponsored clinical trials for Mycobacterium Infections in 2021, over the five-year average of 44.6% and ten-year average of 42.9%.
Phase IV trials held a 30.1% share in 2021, as against the five-year average of 18.9% and ten-year average of 19.4%. Phase III trials held a 23.3% share, compared with the five-year and ten-year averages of 20.7% and 19.4% respectively.
Phase I trials held a 12.3% share in 2021, over the five-year average of 15.9% and ten-year average of 18.3%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
